Advertisement

Journal of Applied Spectroscopy

, Volume 81, Issue 5, pp 812–819 | Cite as

Spectroscopic Study on the Interaction of 4-dimethylaminochalcones with Phospholipids

  • V. Tomečková
  • M. Revická
  • A. Sassen
  • B. Veliká
  • M. Stupák
  • P. Perjési
Article

The ultraviolet-visible and fluorescence spectroscopic properties of 4′-dimethylaminochalcone (1a) and its cyclic analogs 2a–4a have been studied in the presence of phospholipid vesicles (i.e., egg yolk lecithin and dipalmitoylpho sphatidylcholine), bovine serum albumin (BSA), and lipoprotein particles (i.e., bovine serum albumin plus egg yolk lecithin). The spectral results showed that compounds 1a–4a formed hydrophobic interactions with the phospholipids, lipoproteins, and BSA at the polar/nonpolar interface. Compounds 3a and 4a exhibited the strongest hydrophobic interactions of all of the compounds tested towards the phospholipids. Compound 2a gave the best fluorescent fluorophore indicating interactions with the lipids, lipoproteins, and proteins. Fluorescent microscopic imaging of breast cancer cells treated with compounds 1a–4a revealed that they could be used to stain all of the cellular components and destroy the nuclear structure. Compounds 1a–4a were found to be concentrated predominantly on the surfaces of the liposomes and lipoproteins.

Keywords

dimethylaminochalcone fluorescence spectroscopy phospholipids lipoproteins breast cancer cells 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    F. A. Tomas-Barberan and M. N. Clifford, J. Sci. Food Agr., 80, 1024–1032 (2000).CrossRefGoogle Scholar
  2. 2.
    M. L. Go, X. Wu, and X. L. Liu, Curr. Med. Chem., 12, 481–499 (2005).CrossRefGoogle Scholar
  3. 3.
    S. Iwata, N. Nagata, A. Omae, S. Yamaguchi, Y. Okada, S. Shibata, and T. Okuyama, Biol. Pharmaceut. Bull., 22, 323–325 (1999).CrossRefGoogle Scholar
  4. 4.
    H. Kamei, T. Koide, Y. Hashimoto, T. Kojina, and M. Hosegawa, Cancer Biother. Radiopharm., 12, 51–57 (1997).CrossRefGoogle Scholar
  5. 5.
    I. S. Arti, H. Timmerman, S. Sastrohamidjojo, and H. Van der Goot, Eur. J. Med., 35, 449–457 (2000).CrossRefGoogle Scholar
  6. 6.
    M. Pilatova, L. Varinska, P. Perjesi, M. Sarissky, L. Mirossay, P. Solar, A. Ostro, and J. Mojzis, Toxicol. in Vitro, 24, 1347–1355 (2010).CrossRefGoogle Scholar
  7. 7.
    J. R. Dimmock, N. M. Kandepu, A. J. Nazarali, T. P. Kowalchuk, N. Motaganahalli, J. W. Quail, P. A. Mykytiuk, G. F. Audette, L. Prasad, P. Perjési, T. M. Allen, C. L. Santos, J. Szydlowski, E. De Clercq, and J. Balzarini, J. Med. Chem., 22, 1358–1366 (1999).CrossRefGoogle Scholar
  8. 8.
    J. R. Dimmock, G. A. Zello, E. O. Oloo, J. W. Quail, H. B. Kraatz, P. Perjési, F. Aradi, K. Takács-Novák, T. M. Allen, C. L. Santos, J. Balzarini, E. De Clercq, and J. P. Stables, Med. Chem., 45, 3103–3111 (2002).CrossRefGoogle Scholar
  9. 9.
    P. Perjési, U. Das, E. De Clercq, J. Balzarini, M. Kawase, H. Sakagami, J. P. Stables, T. Lorand, Z. Rozmer, and J. R. Dimmock, Eur. J. Med. Chem., 43, 839–845 (2008).CrossRefGoogle Scholar
  10. 10.
    P. Perjési and Z. Rozmer, The Open Med. Chem. J., 5, 61–67 (2011).CrossRefGoogle Scholar
  11. 11.
    P. Perjési, A. Perjessy, E. Kolehmainen, E. Ősz, M. Samalikova, and E. Virtanen, J. Mol. Struct., 697, 41–47 (2004).ADSCrossRefGoogle Scholar
  12. 12.
    P. Perjési, J. Linnanto, E. Kolehmainen, E. Õsz, and E. Virtanen, J. Mol. Struct., 740, 81–89 (2005).ADSCrossRefGoogle Scholar
  13. 13.
    V. Tomečková, M. Poškrobová, M. Štefanišinová, and P. Perjési, Spectrochim Acta Part A: Mol. Biomol. Spectrosc., 74, 1242–1246 (2009).ADSCrossRefGoogle Scholar
  14. 14.
    K. Fodor, V. Tomeckova, T. Kőszegi, I. Kron, and P. Perjési, Monatsh. Chem., 142, 463–468 (2011).CrossRefGoogle Scholar
  15. 15.
    C. H. Zhang, Z. B. Chen, and Y. B. Jiang, Spectrochim. Acta, A: Mol. Biomol. Spectrosc., 60, 2729–2732 (2004).ADSCrossRefGoogle Scholar
  16. 16.
    A. P. Demchenko, Y. Mély, G. Duportail, and A. S. Klymchenko, Biophys. J., 96, 3461–3470 (2009).ADSCrossRefGoogle Scholar
  17. 17.
    G. E. Dobretsov, V. V. Kosnikov, S. S. Shanin, E. M. Kogan, and I. A. Vladimirov, Tsitologiia, 22, 320–325 (1980).Google Scholar
  18. 18.
    S. K. Gularyan, V. Y. Svetlichny, and G. E. Dobretsov, Membr. Cell. Biol., 11, 401–410 (1997).Google Scholar
  19. 19.
    O. L. Kulagin, Eksp. Klin. Farmakol., 63, 44–46 (2000).Google Scholar
  20. 20.
    N. A. Burmistrova, S. P. Mushtakova, and P. E. Kuznetsov, J. Anal. Chem., 61, 1286–1289 (2006).Google Scholar
  21. 21.
    V. Tomečková, P. Perjési, J. Guzy, J. Kusnír, Z. Chovanová, Z. Chavková, and M. Mareková, J. Biochem. Biophys. Methods, 61, 135–141 (2004).CrossRefGoogle Scholar
  22. 22.
    M. Štefanišinová, V. Tomečková, M. Kožurková, A. Ostró, and M. Mareková, Spectrochim. Acta, A: Mol. Biomol. Spectrosc., 81, 666–671 (2011).CrossRefGoogle Scholar
  23. 23.
    P. Perjési, T. Nusser, G. Tarczay, and P. Sohár, J. Mol. Struct., 479, 13–19 (1999).ADSCrossRefGoogle Scholar
  24. 24.
    G. E. Dobretsov, V. A. Petrov, V. E. Mishijev, G. I. Klebanov, and Y. A. Vladimirov, Stud. Biophys., 62, 91–98 (1977).Google Scholar
  25. 25.
    V. Y. Svetlichny, F. Merola, G. E. Dobretsov, S. K. Gularyan, and T. I. Syrejshchikova, Chem. Phys. Lipids, 145, 13–26 (2007).CrossRefGoogle Scholar
  26. 26.
    M. Kriechbaum, O. Wolfbeis, and E. Koller, Chem. Phys. Lipids, 44, 19–29 (1987).CrossRefGoogle Scholar
  27. 27.
    A. S. Klymchenko, G. Duportail, A. P. Demchenko, and Y. Mély, Biophys. J., 86, 2929–2941 (2004).ADSCrossRefGoogle Scholar
  28. 28.
    K. Takács-Novák, P. Perjési, and J. Vámos, J. Planar. Chromatogr., 14, 42–46 (2001).Google Scholar
  29. 29.
    S. K. Gularyan, G. E. Dobretsov, and V. Y. Svetlichny, Biophysics, 48, 873–879 (2003).Google Scholar
  30. 30.
    J. Kubalková, V. Tomečková, P. Perjési, and J. Guzy, Centr. Eur. J. Biol., 4, 90–96 (2009).CrossRefGoogle Scholar
  31. 31.
    Z. Rozmer, T. Berki, and P. Perjési, Toxicol. In Vitro, 20, 1354–1362 (2006).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • V. Tomečková
    • 1
  • M. Revická
    • 1
  • A. Sassen
    • 2
  • B. Veliká
    • 1
  • M. Stupák
    • 1
  • P. Perjési
    • 3
  1. 1.Department of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of MedicineUPJŠKošiceSlovakia
  2. 2.Institute of PathologyUniversity of RegensburgRegensburgGermany
  3. 3.Institute of Pharmaceutical ChemistryUniversity of PécsPécsHungary

Personalised recommendations